KR101676454B1 - 약물 조합 및 기침 질환의 치료 용도 - Google Patents

약물 조합 및 기침 질환의 치료 용도 Download PDF

Info

Publication number
KR101676454B1
KR101676454B1 KR1020147002930A KR20147002930A KR101676454B1 KR 101676454 B1 KR101676454 B1 KR 101676454B1 KR 1020147002930 A KR1020147002930 A KR 1020147002930A KR 20147002930 A KR20147002930 A KR 20147002930A KR 101676454 B1 KR101676454 B1 KR 101676454B1
Authority
KR
South Korea
Prior art keywords
day
cough
delete delete
theobromine
methylxanthine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020147002930A
Other languages
English (en)
Korean (ko)
Other versions
KR20140037947A (ko
Inventor
존 브류
로빈 마크 배니스터
Original Assignee
인퍼스트 헬스케어 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 인퍼스트 헬스케어 리미티드 filed Critical 인퍼스트 헬스케어 리미티드
Publication of KR20140037947A publication Critical patent/KR20140037947A/ko
Application granted granted Critical
Publication of KR101676454B1 publication Critical patent/KR101676454B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A61K31/09—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/02—Ammonia; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020147002930A 2011-07-05 2012-04-13 약물 조합 및 기침 질환의 치료 용도 Expired - Fee Related KR101676454B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1111485.7 2011-07-05
GBGB1111485.7A GB201111485D0 (en) 2011-07-05 2011-07-05 Drug composition and its use in therapy
PCT/GB2012/050816 WO2013004999A1 (en) 2011-07-05 2012-04-13 Drug combinations and uses in treating a coughing condition

Publications (2)

Publication Number Publication Date
KR20140037947A KR20140037947A (ko) 2014-03-27
KR101676454B1 true KR101676454B1 (ko) 2016-11-15

Family

ID=44512137

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020147002930A Expired - Fee Related KR101676454B1 (ko) 2011-07-05 2012-04-13 약물 조합 및 기침 질환의 치료 용도

Country Status (12)

Country Link
EP (2) EP3251665A1 (enExample)
JP (2) JP2014518252A (enExample)
KR (1) KR101676454B1 (enExample)
CN (1) CN103648488A (enExample)
AU (2) AU2012280019B2 (enExample)
BR (1) BR112014000159A2 (enExample)
CA (1) CA2840793A1 (enExample)
GB (1) GB201111485D0 (enExample)
MX (1) MX2014000129A (enExample)
RU (2) RU2016101054A (enExample)
WO (1) WO2013004999A1 (enExample)
ZA (1) ZA201400010B (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201111485D0 (en) * 2011-07-05 2011-08-17 Biocopea Ltd Drug composition and its use in therapy
GB0910375D0 (en) 2009-06-16 2009-07-29 Biocopea Ltd Drug composition and its use in therapy
GB201014391D0 (en) * 2010-08-27 2010-10-13 Biocopea Ltd Drug composition and its use in therapy
US9314465B2 (en) 2009-06-16 2016-04-19 Infirst Healthcare Limited Drug combinations and uses in treating a coughing condition
US10016437B2 (en) 2009-06-16 2018-07-10 Infirst Healthcare Limited Drug combinations and uses in treating a coughing condition
US9308211B2 (en) 2009-06-16 2016-04-12 Infirst Healthcare Limited Drug combinations and uses in treating a coughing condition
US9757395B2 (en) 2012-12-20 2017-09-12 Otitopic Inc. Dry powder inhaler and methods of use
US9757529B2 (en) 2012-12-20 2017-09-12 Otitopic Inc. Dry powder inhaler and methods of use
JP2016518388A (ja) 2013-04-30 2016-06-23 オティトピック インク． 乾燥粉末配合および使用方法
BR112017004533A2 (pt) * 2014-09-08 2018-05-08 Gotham Biopharmaceuticals Inc método para tratamento de sarcoidose pulmonar
CN104436176A (zh) * 2014-11-17 2015-03-25 华东理工大学 一种基于上呼吸道感染及肺炎用的新型生物抗菌喷雾剂
US10786456B2 (en) 2017-09-22 2020-09-29 Otitopic Inc. Inhaled aspirin and magnesium to treat inflammation
KR102507987B1 (ko) 2017-09-22 2023-03-21 벡추라 인코포레이티드 스테아르산마그네슘을 갖는 건조 분말 조성물
US12459965B2 (en) 2017-10-09 2025-11-04 Compass Pathfinder Limited Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
CN109793823A (zh) * 2017-11-17 2019-05-24 中国科学院大连化学物理研究所 一种外用止咳平喘软膏剂及其制备方法
MX2021000908A (es) * 2018-07-23 2021-06-08 Trevi Therapeutics Inc Tratamiento de la tos cronica, la dificultad respiratoria y la disnea.
AU2020258086A1 (en) 2019-04-17 2021-11-11 Compass Pathfinder Limited Methods of treating neurocognitive disorders, chronic pain and reducing inflammation
US20240122934A1 (en) * 2019-10-16 2024-04-18 University Of South Florida Compositions and methods of treatment for inhibiting capillary tube regression
WO2021138578A1 (en) * 2019-12-31 2021-07-08 The Trustees Of Indiana University Repurposing fda-approved drugs as a novel cancer therapeutic avenue through inhibition of prmt5
EP4087569A4 (en) 2020-01-10 2024-01-24 Trevi Therapeutics, Inc. METHODS OF ADMINISTRATION OF NALBUPHINE
US11628165B1 (en) * 2020-03-25 2023-04-18 Helen Feng Method of boosting immune system against viral infection

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011058373A2 (en) * 2009-11-13 2011-05-19 Biocopea Limited Drug combination with theobromine and its use in therapy
WO2011073646A1 (en) * 2009-12-14 2011-06-23 Biocopea Limited Combination of theobromine with a decongestant and its use for the treatment of cough

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4756911A (en) 1986-04-16 1988-07-12 E. R. Squibb & Sons, Inc. Controlled release formulation
US5378475A (en) 1991-02-21 1995-01-03 University Of Kentucky Research Foundation Sustained release drug delivery devices
US5869079A (en) 1995-06-02 1999-02-09 Oculex Pharmaceuticals, Inc. Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents
US20020009478A1 (en) * 1998-08-24 2002-01-24 Douglas Joseph Dobrozsi Oral liquid mucoadhesive compositions
JP2002363072A (ja) * 2001-04-03 2002-12-18 Taisho Pharmaceut Co Ltd 鎮咳用組成物
JP2003081821A (ja) * 2001-09-12 2003-03-19 Taisho Pharmaceut Co Ltd 医薬組成物
JP4377564B2 (ja) * 2002-05-02 2009-12-02 ロート製薬株式会社 内服用組成物
US6979689B2 (en) * 2002-12-20 2005-12-27 Pediamed Pharmaceuticals, Inc. Compositions and methods for treating upper respiratory congestion
US20050152967A1 (en) * 2003-03-28 2005-07-14 Pfab, Lp Dynamic variable release
AU2005209201B2 (en) 2004-01-20 2010-06-03 Allergan, Inc. Compositions for localized therapy of the eye, comprising preferably triamcinolone acetonide and hyaluronic acid
US7799336B2 (en) 2004-04-30 2010-09-21 Allergan, Inc. Hypotensive lipid-containing biodegradable intraocular implants and related methods
JP4195895B2 (ja) * 2006-04-04 2008-12-17 小林製薬株式会社 吐出装置を備えた容器に収容される経口投与用液体医薬製剤
US20080003280A1 (en) * 2006-06-26 2008-01-03 Levine Brian M Combination cough treatment compounds and method of treating common coughs
US8420077B2 (en) 2009-04-20 2013-04-16 Allergan, Inc. Silk fibroin hydrogels and uses thereof
GB0921803D0 (en) * 2009-12-14 2010-01-27 Biocopea Ltd Drug composition and its use in therapy
GB201014391D0 (en) * 2010-08-27 2010-10-13 Biocopea Ltd Drug composition and its use in therapy
GB201111485D0 (en) * 2011-07-05 2011-08-17 Biocopea Ltd Drug composition and its use in therapy
GB0919893D0 (en) * 2009-11-13 2009-12-30 Biocopea Ltd Drug composition and its use in therapy
UA47594U (uk) * 2009-09-17 2010-02-10 Игорь Викторович Трутаев Комбінований засіб для лікування та профілактики захворювань дихальних шляхів
JP5815226B2 (ja) * 2009-11-30 2015-11-17 興和株式会社 ロキソプロフェンを含有する医薬組成物

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011058373A2 (en) * 2009-11-13 2011-05-19 Biocopea Limited Drug combination with theobromine and its use in therapy
WO2011073646A1 (en) * 2009-12-14 2011-06-23 Biocopea Limited Combination of theobromine with a decongestant and its use for the treatment of cough

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
The FASEB journal, Vol. 19, pp. 231-233, 2005.*

Also Published As

Publication number Publication date
CA2840793A1 (en) 2013-01-10
RU2016101054A (ru) 2018-11-19
ZA201400010B (en) 2015-04-29
EP2729136A1 (en) 2014-05-14
BR112014000159A2 (pt) 2020-10-27
AU2016256741A1 (en) 2016-12-01
RU2016101054A3 (enExample) 2018-11-19
JP2018048189A (ja) 2018-03-29
RU2014103787A (ru) 2015-08-20
MX2014000129A (es) 2014-05-28
GB201111485D0 (en) 2011-08-17
AU2012280019B2 (en) 2016-10-27
EP3251665A1 (en) 2017-12-06
JP2014518252A (ja) 2014-07-28
WO2013004999A1 (en) 2013-01-10
CN103648488A (zh) 2014-03-19
KR20140037947A (ko) 2014-03-27
AU2012280019A1 (en) 2014-01-23

Similar Documents

Publication Publication Date Title
KR101676454B1 (ko) 약물 조합 및 기침 질환의 치료 용도
US8729070B2 (en) CNS pharmaceutical compositions and methods of use
US20160120899A1 (en) Drug Combinations and Uses in Treating a Coughing Condition
CA2716080C (en) Cns pharmaceutical compositions and methods of use
JP2000508341A (ja) 片頭痛の治療法及び薬効の強化組成物
CN106714790A (zh) 使用β肾上腺素能受体拮抗剂和毒蕈碱受体拮抗剂组合的治疗惊恐和焦虑症状的药物组合物和方法
JP2003176240A (ja) ニコチン性アセチルコリン受容体作用薬により関節の潤滑を高める方法
JPH10505087A (ja) 非麻薬性鎮痛剤および無痛エンハンサーを含有する疼痛緩和組成物
US10420812B2 (en) Drug combinations and uses in treating a coughing condition
US20160271136A1 (en) Drug Combinations and Uses in Treating a Coughing Condition
US9700561B2 (en) Drug combinations and uses in treating a coughing condition
US9675618B2 (en) Drug combinations and uses in treating a coughing condition
US10016437B2 (en) Drug combinations and uses in treating a coughing condition
WO2016027259A1 (en) Cns pharmaceutical compositions and methods of use
US9238014B2 (en) Pharmaceutical composition for treating alcohol dependency
US9463191B2 (en) Pharmaceutical compositions
CA2623184A1 (en) Combination s-nitrosothiol-based pharmaceutical products for restoring normal breathing rhythm

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

A201 Request for examination
AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

N231 Notification of change of applicant
PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

N231 Notification of change of applicant
PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

AMND Amendment
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PX0901 Re-examination

St.27 status event code: A-2-3-E10-E12-rex-PX0901

PX0701 Decision of registration after re-examination

St.27 status event code: A-3-4-F10-F13-rex-PX0701

X701 Decision to grant (after re-examination)
GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

R17-X000 Change to representative recorded

St.27 status event code: A-5-5-R10-R17-oth-X000

R17-X000 Change to representative recorded

St.27 status event code: A-5-5-R10-R17-oth-X000

PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20191110

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20191110